ASH 2014 | ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 1)

Jia Ruan

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results.

Share this video  
5th December 2014